viewAnteris Technologies Ltd

Anteris Technologies boosts funds with $1.49 million R&D refund

It will repay the short-term facility entered into with Mitchell Asset Management for the advance of $1.22 million for its forecasted R&D tax incentive.

Anteris Technologies Ltd - Anteris Technologies boosts funds with $1.49 million R&D refund
The claim covers the year ended 31 December 2020.

Anteris Technologies Ltd (ASX:AVR) (FRA:DDF) has received $1.49 million under the Australian Government’s Research and Development (R&D) Tax Incentive Scheme for the year ended 31 December 2020. 

The company will now repay the short-term facility entered into with Mitchell Asset Management Pty Ltd at the end of 2020 for the advance of $1.22 million, which provided immediate funds equivalent to its forecasted R&D tax incentive offset for the majority of the 2020 calendar year.

R&D tax incentive

The Australian Government’s R&D Tax Incentive encourages companies to engage in R&D, by providing a refundable tax offset for eligible R&D activities - assisting businesses to recover some of their costs related to R&D.

The R&D refund confirms Anteris’ significant and ongoing commitment to invest in, research and develop its ADAPT® technology and product development pipeline including DurAVR™, its 3D single-piece aortic valve.

Aortic replacement valve

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT® tissue technology, paired with DurAVR™’s unique 3D single-piece aortic valve design, have the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

Quick facts: Anteris Technologies Ltd


Price: 8.42 AUD

Market Cap: $67.87 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Anteris Technologies 'sitting on a significantly large opportunity' as it...

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson speaks to Proactive following the company's AGM. It's recently achieved a breakthrough in manufacturing the tissue used in ADAPT® treated products from bovine pericardium, after developing specialised machinery to create consistently thin...

on 15/7/21

2 min read